US EditionIMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC - ILCN.org (ILCN/WCLC)
Summary by ILCN.org (ILCN/WCLC)
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC - ILCN.org (ILCN/WCLC)
The IMpower010 trial has previously demonstrated improvements in disease-free survival (DFS) compared with best supportive care (BSC) for patients with resected stage II-IIIA non-small cell lung cancer (NSCLC). While the trial did not achieve the statistical significance boundary in the intent-to-treat (ITT) population during its first interim analysis, recently published 5-year data as well as an exploratory, retrospective analysis of genomic p…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
